

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

FIG. 1




Fig.2A Fig.2B Fig.2C





Fig.2D




Fig.2E

	230	240	250	260	270
humIgG1	PAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYV				
humIgG2	PAP - PVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFNWYV				
humIgG3	PAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFKWYV				
humIgG4	PAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSEQEDPEVQFNWYV				
murIgG1	- - -TVPEVSSVFIFPPKPKDVLITITLTPKVTCVVVDISKDDPEVQFSWFV				
murIgG2A	PAPNLLGGPSVFIFFPKIKDVLMISSLPIVTCVVVDVSEDDPDVQISWFV				
murIgG2B	PAPNLEGGPSVFIFFPNIKDVLMISSLTPKVTCVVVDVSEDDPDVQISWFV				
murIgG3	PPGNILGGPSVFIFFPKPKDALMISSLTPKVTCVVVDVSEDDPDVHVSWFV				
	280	290	300	310	320
humIgG1	DGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALP				
humIgG2	DGVEVHNAKTKPREEQFNSTFRVSVLTVVHQDWLNGKEYKCKVSNKGLP				
humIgG3	DGVEVHNAKTKPREEQFNSTFRVSVLTVLHQDWLNGKEYKCKVSNKALP				
humIgG4	DGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLP				
murIgG1	DDVEVHTAQTQPREEQFNSTFRSVSELPIMHQDCLNGKEFKCRVNSAAFP				
murIgG2A	NNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLP				
murIgG2B	NNVEVHTAQTQTHREDYNSTIRVVSHPILPIQHQDWMSGKEFKCKVNNKDLP				
murIgG3	DNKEVHTAWTQPREAQYNSTFRVVSALPIQHQDWMRGKEFKCKVNNKALP				
	330	340	350	360	370
humIgG1	APIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAV				
				D L	
humIgG2	APIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAV				
humIgG3	APIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAV				
humIgG4	SSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAV				
murIgG1	APIEKTISKTKGRPKAPQVYTIPPPKEQMAKDKVSLTCMITDFFPEDITV				
murIgG2A	APIERTISKPKGSVRAPQVYVLPPEEEMTKKQVTLTCMVTDFFMPEDIYV				
murIgG2B	SPIERTISKPKGLVRAPQVYTLPPPAEQLSRKDVSLTCLVVGFNPGDISV				
murIgG3	APIERTISKPKGRAQTPQVYTIPPPREQMSKKKVSILTCLVTNFFSEAISV				
	380	390	400	410	420
humIgG1	EWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSQSVMH				
humIgG2	EWESNGQPENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQGNVFSQSVMH				
humIgG3	EWESSGQPENNYNTTPPMLDSDGSFFLYSKLTVDKSRWQQGNIFQSVMH				
humIgG4	EWZSNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSQSVMH				
murIgG1	EWQWNGQPAENYKNTQPIMDTDGSYFVYSKLNQKSNWEAGNTFTCSVLH				
murIgG2A	EWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSQSVVH				
murIgG2B	EWTSNNGHTEENYKDTAPVLDSDGSYFIYSKLNMKTSKWEKTDSFSCNVRH				
murIgG3	EWERNGELEQDYKNTPPILDSGTYFLYSKLTVDTDVSWLQGEIFTCSVVH				
	430	440			
humIgG1	EALHNHYTQKSLSLSPGK				
humIgG2	EALHNHYTQKSLSLSPGK				
humIgG3	EALHNRFTQKSLSLSPGK				
humIgG4	EALHNHYTQKSLSLSPGK				
murIgG1	EGLHNHHTTEKSLSHSPGK				
murIgG2A	EGLHNHHTTKSFSRTPGK				
murIgG2B	EGLKNYYLKKKTISRSPGK				
murIgG3	EALHNHHTQKNLSRSPGK				

Figure 3

Fig.4A






Fig.4B



Light chain
Heavy chain

Fig. 5



HERCEPTIN[®] is a registered trademark of Genentech, Inc.




Fig. 6A




Fig. 6B





Fig. 6C

Fig. 7











Fig.9






Fig. 10A

Fig. 10B

Fig. 11 A-F




Fig. 11G




Fig. 11H

OctHER2 - 5hr

Multivesicular
Body




Fig. 11 I



Fig. 12A




Fig. 12B





Fig. 12C




Fig. 12D




Fig. 12E

Fig. 13A




Fig. 13C





Fig. 13B




Fig. 13D

Fig. 14




Fig. 15




Figure 16: Dose-response curves for the inhibition of 3H3 octopus by 16E2 octopus 3.0A, 16E2 octopus 2.1, 16E2 octopus 2.6, 16E2 octopus 3.0B, and 16E2 octopus 5.8. The x-axis represents the concentration in ng/ml on a log scale, and the y-axis represents the percentage of control activity.

Fig. 16




Fig. 17A




Fig. 17B










Fig. 18 A




16E2 Octopus (anti-DR5) - 2 day




APO2L - 2 day

Fig. 18 B

Figure 18B shows the effect of 16E2 Octopus (anti-DR5) on the growth of various human cancer cell lines. The graphs show the percentage growth of the cells over a 2-day period for different concentrations of the antibody. The cell lines are grouped by cancer type: CNS Cancer, Melanoma, and Ovarian Cancer. Each graph plots Percentage Growth (Y-axis, 0 to 100) against Log₁₀ of Sample Concentration (Vol. Dil.) (X-axis, 0 to 2). The legend for each graph indicates the specific cell lines and the antibody concentration used.




16E2 Octopus (anti-DR5) - 2 day




APO2L - 2 day

Fig. 18 C

16E2 Octopus (anti-DR5) - 2 day




16E2 Octopus (anti-DR5) - 2 day




APO2L - 2 day

Fig. 19 A

Figure 19A shows the effect of 16E2 Octopus (anti-DR5) on the growth of various cancer cell lines. The graphs show the percentage growth of the cells over a 6-day period, plotted against the log10 of the sample concentration (Vol. Dil.). The cell lines tested are Leukemia, Non-Small Cell Lung Cancer, and Colon Cancer. The data is presented for three different cell lines: HL-607B, K-562, and MOLT-4 (Leukemia); A549ATCC, EKVX, HOP-43, NCI-H460, NCI-H323, and HOP-92 (Non-Small Cell Lung Cancer); and COLO-205, HCT-116, HCT-15, and SW-620 (Colon Cancer). The graphs show that the growth of the cells is generally inhibited by the treatment, with the most significant inhibition observed in the Non-Small Cell Lung Cancer cell lines.




16E2 Octopus (anti-DR5) - 6 day




APO2L - 6 day

Fig. 19 B






16E2 Octopus (anti-DR5) - 6 day






APO2L - 6 day

Fig. 19 C



16E2 Octopus (anti-DR5) - 6 day



APO2L - 6 day

Fig. 20 A

16E2 Octopus (anti-DR5) 12 day

Panel/Cell Line	Time Zero	Ctrl	Mean Optical Densities				Log10 Concentration				Percent Growth				GI50	TCI	LC50
			0.5	1.0	1.5	2.0	0.5	1.0	1.5	2.0	0.5	1.0	1.5	2.0			
Leukemia	CCRF-CEM	0.081	0.557	0.526	0.491	0.457	0.299	0.125	94	86	79	46	9	2.74E+01	>1.00E+02	>1.00E+02	>1.00E+02
	HL-60(TB)	0.487	1.935	1.821	1.827	1.486	0.843	0.561	92	93	69	25	5	1.64E+01	>1.00E+02	>1.00E+02	>1.00E+02
	K-562	0.238	1.548	1.525	1.473	1.494	1.458	1.00	98	94	96	93		>1.00E+02	>1.00E+02	>1.00E+02	
	MOLT-4	0.215	1.046	0.976	0.908	0.890	0.888	0.874	92	83	81	79		>1.00E+02	>1.00E+02	>1.00E+02	
	RPMI-8226	0.335	1.302	1.067	1.009	0.947	0.937	0.959	76	70	63	62	65	>1.00E+02	>1.00E+02	>1.00E+02	
	SR	0.279	1.868	0.965	0.807	0.681	0.600	0.537	43	33	25	20	16	<1.00E+00	>1.00E+02	>1.00E+02	
Non-Small Cell Lung Cancer	A549/ATCC	0.212	1.132	1.155	1.091	1.061	1.094	1.096	102	95	92	96	96	>1.00E+02	>1.00E+02	>1.00E+02	
	EBVX	0.361	1.345	1.247	1.256	1.237	1.142	1.181	87	89	86	74	79	>1.00E+02	>1.00E+02	>1.00E+02	
	HOP-62	0.363	1.082	1.147	1.156	1.191	1.182	1.158	109	110	115	114	111	>1.00E+02	>1.00E+02	>1.00E+02	
	HOP-92	0.630	0.958	0.717	0.617	0.541	0.551	0.564	26	-2	-14	-13	-10	<1.00E+00	2.92E+00	>1.00E+02	
	NCI-H226	0.269	0.702	0.660	0.588	0.531	0.541	0.539	90	74	61	63	62	>1.00E+02	>1.00E+02	>1.00E+02	
	NCI-H23	0.602	1.657	1.581	1.525	1.463	1.540	1.540	93	88	82	86	89	>1.00E+02	>1.00E+02	>1.00E+02	
	NCI-H322H	0.488	1.265	1.222	1.265	1.256	1.276	1.211	94	100	99	101	93	>1.00E+02	>1.00E+02	>1.00E+02	
	NCI-H460	0.362	1.677	0.416	0.305	0.244	0.256	0.237	4	-16	-33	-29	-35	<1.00E+00	1.27E+00	>1.00E+02	
	NCI-H522	0.374	0.954	0.868	0.830	0.804	0.828	0.839	85	79	74	78	80	>1.00E+02	>1.00E+02	>1.00E+02	
	Colon Cancer	COLO 205	0.145	0.829	0.003	-0.002	-0.008	0.004	0.009	-98	-100	-100	-98	-94	<1.00E+00	<1.00E+00	<1.00E+00
HCC-2998	0.334	0.797	0.511	0.353	0.246	0.250	0.252	38	4	-26	-25	-25	<1.00E+00	3.70E+00	>1.00E+02		
HCT-116	0.385	2.058	1.341	1.051	1.008	0.926	0.904	57	40	37	32	31	1.61E+00	>1.00E+02	>1.00E+02		
HCT-15	0.205	1.218	0.324	0.204	0.146	0.154	0.169	12	0	-29	-25	-18	<1.00E+00	3.03E+00	>1.00E+02		
HCT-19	0.322	1.464	1.547	1.523	1.566	1.553	1.485	107	105	109	108	102	>1.00E+02	>1.00E+02	>1.00E+02		
KM12	0.240	1.281	1.243	1.218	1.224	1.096	1.097	96	94	95	82	82	>1.00E+02	>1.00E+02	>1.00E+02		
SW-620	0.134	0.961	0.713	0.721	0.678	0.645	0.594	70	71	66	62	56	>1.00E+02	>1.00E+02	>1.00E+02		
CNS Cancer	SF-268	0.360	1.045	1.005	1.008	0.992	1.013	0.970	94	94	92	95	89	>1.00E+02	>1.00E+02	>1.00E+02	
	SF-295	0.512	1.311	0.344	0.313	0.312	0.313	0.282	-33	-39	-39	-39	-45	<1.00E+00	<1.00E+00	<1.00E+00	
	SF-539	0.220	1.153	0.860	0.750	0.673	0.674	0.657	69	57	49	49	47	8.14E+00	>1.00E+02	>1.00E+02	
	SNB-19	0.316	1.123	1.139	1.143	1.121	1.136	1.157	102	102	100	102	104	>1.00E+02	>1.00E+02	>1.00E+02	
	SNB-75	0.326	0.637	0.651	0.640	0.596	0.623	0.628	104	101	87	96	97	>1.00E+02	>1.00E+02	>1.00E+02	
	U251	0.197	0.981	0.766	0.718	0.642	0.620	0.636	73	66	57	54	56	>1.00E+02	>1.00E+02	>1.00E+02	
	Melanoma	LOX IMVI	0.349	1.703	1.589	1.510	1.366	1.321	1.299	92	86	75	72	70	>1.00E+02	>1.00E+02	>1.00E+02
	MALME-JM	0.350	0.732	0.643	0.600	0.555	0.537	0.553	77	65	53	54	53	>1.00E+02	>1.00E+02	>1.00E+02	
	M14	0.320	1.246	0.982	0.783	0.716	0.689	0.703	72	50	43	40	41	<1.00E+00	>1.00E+02	>1.00E+02	
	SK-MEL-2	0.592	0.982	0.758	0.712	0.639	0.618	0.622	43	31	12	7	8	<1.00E+00	>1.00E+02	>1.00E+02	
SK-MEL-28	0.345	1.033	0.853	0.835	0.768	0.729	0.668	74	71	61	56	47	6.76E+01	>1.00E+02	>1.00E+02		
SK-MEL-5	0.346	2.111	1.937	1.893	1.770	1.869	1.721	90	88	81	86	78	>1.00E+02	>1.00E+02	>1.00E+02		
UACC-257	0.612	1.307	1.211	1.133	1.062	1.053	0.976	86	75	65	63	52	>1.00E+02	>1.00E+02	>1.00E+02		
UACC-62	0.597	1.806	1.509	1.318	1.166	1.038	1.024	75	60	47	36	35	7.66E+00	>1.00E+02	>1.00E+02		
Ovarian Cancer	IGROV1	0.209	0.934	0.927	0.876	0.915	0.905	0.893	99	92	97	96	94	>1.00E+02	>1.00E+02	>1.00E+02	
	OVCAR-3	0.434	1.295	0.566	0.526	0.460	0.439	0.431	15	11	3	1	-1	<1.00E+00	5.13E+01	>1.00E+02	
	OVCAR-4	0.359	1.495	1.464	1.453	1.442	1.404	1.361	97	96	95	92	88	>1.00E+02	>1.00E+02	>1.00E+02	
	OVCAR-5	1.107	1.829	1.539	1.355	1.318	1.181	1.253	60	34	29	10	20	1.56E+00	>1.00E+02	>1.00E+02	
	OVCAR-8	0.238	0.890	0.903	0.875	0.881	0.923	0.882	102	98	99	105	99	>1.00E+02	>1.00E+02	>1.00E+02	
	SK-OV-3	0.450	1.051	1.051	1.061	1.034	1.068	1.075	100	102	97	103	104	>1.00E+02	>1.00E+02	>1.00E+02	
	Renal Cancer	786-0	0.453	1.495	1.504	1.506	1.492	1.491	1.512	101	101	100	100	102	>1.00E+02	>1.00E+02	>1.00E+02
	A498	0.757	1.482	1.350	0.968	0.743	0.690	0.726	54	29	-2	-9	44	1.21E+00	9.31E+00	>1.00E+02	
	ACHN	0.360	1.644	1.336	1.290	0.931	0.904	0.899	76	72	44	42	42	7.98E+00	>1.00E+02	>1.00E+02	
	CAKI-1	0.292	1.410	1.326	1.213	1.151	1.071	1.062	93	82	77	70	69	>1.00E+02	>1.00E+02	>1.00E+02	
RXFP 393	0.546	1.151	1.107	1.203	1.149	1.156	1.157	93	109	100	101	101	>1.00E+02	>1.00E+02	>1.00E+02		
SN12C	0.511	1.145	0.962	0.839	0.755	0.730	0.788	71	52	39	34	44	3.70E+00	>1.00E+02	>1.00E+02		
TK-10	0.539	1.127	1.116	1.095	1.021	1.028	0.999	98	95	82	83	78	>1.00E+02	>1.00E+02	>1.00E+02		
DO-31	0.580	1.330	1.391	1.351	1.319	1.301	1.294	108	103	99	96	95	>1.00E+02	>1.00E+02	>1.00E+02		
Prostate Cancer	PC-3	0.332	0.865	0.653	0.628	0.546	0.545	0.552	60	55	40	40	41	4.75E+00	>1.00E+02	>1.00E+02	
	DU-145	0.336	1.268	1.174	1.189	1.130	1.115	1.112	90	91	85	85	83	>1.00E+02	>1.00E+02	>1.00E+02	
	Brast Cancer	MDA-MB-231	0.361	1.913	1.881	1.935	1.827	1.950	2.020	98	101	94	102	107	>1.00E+02	>1.00E+02	>1.00E+02
Breast Cancer	MDA-MB-231/ATCC	0.331	0.988	0.958	0.976	0.977	0.992	0.996	95	98	96	101	101	>1.00E+02	>1.00E+02	>1.00E+02	
	MDA-MB-435	0.590	0.974	0.998	0.958	0.883	0.895	0.887	106	96	76	79	77	>1.00E+02	>1.00E+02	>1.00E+02	
	MDA-MB-435	0.578	1.268	1.146	1.028	0.976	0.977	1.018	82	65	58	58	64	>1.00E+02	>1.00E+02	>1.00E+02	
	MDA-MB-435	0.561	1.249	1.055	0.972	0.858	0.843	0.783	80	72	60	59	53	>1.00E+02	>1.00E+02	>1.00E+02	
	MDA-N	0.217	0.971	0.910	0.895	0.782	0.795	0.766	92	90	75	77	73	>1.00E+02	>1.00E+02	>1.00E+02	
	MDA-N	0.570	1.446	1.237	0.989	0.820	0.773	0.728	76	48	29	23	18	2.90E+00	>1.00E+02	>1.00E+02	
	T-47D	0.382	1.004	0.963	0.993	1.010	1.013	1.026	93	98	101	101	103	>1.00E+02	>1.00E+02	>1.00E+02	

Fig. 20 B

Figure 20B shows the results of the APO2L - 2 day assay. The data is presented in a table format, showing the mean optical densities and percent growth for various cell lines and treatments.

Panel/Cell Line	Time Zero	Ctrl	Log10 Concentration				Percent Growth				G150	TGI	LC50
			0.5	1.0	1.5	2.0	0.5	1.0	1.5	2.0			
Leukemia	CCRF-CEM	0.081	0.576	0.400	0.510	0.443	0.447	0.476	64	87	73	74	80
	HL-60(TB)	0.487	1.926	1.660	1.118	1.074	0.881	0.857	82	44	41	27	26
	K-562	0.238	1.596	1.629	1.557	1.416	1.371	1.349	102	97	87	83	82
	MOLT-4	0.215	1.326	1.132	1.131	1.136	1.167	1.161	101	101	101	101	104
	RFPL-8226	0.335	1.284	0.599	0.427	0.348	0.359	0.345	28	10	1	2	1
	SR	0.279	1.820	1.578	1.475	1.417	1.428	1.460	84	78	74	75	77
	Non-Small Cell Lung Cancer												
	A549/ATCC	0.212	1.164	1.177	1.173	1.086	1.052	1.068	101	101	92	88	90
	FXVX	0.561	1.328	1.325	1.337	1.228	1.275	1.266	100	101	87	93	92
	HOP-62	0.363	1.260	1.241	1.174	1.106	1.202	1.136	98	90	83	94	86
Colon Cancer	HOP-92	0.630	1.002	0.843	0.788	0.755	0.753	0.766	57	43	33	33	37
	NCI-H226	0.269	0.842	0.651	0.691	0.677	0.665	0.663	102	113	109	106	106
	NCI-H23	0.602	1.620	1.597	1.636	1.626	1.641	1.670	98	102	101	102	105
	NCI-H322M	0.488	1.265	1.138	1.054	0.821	0.808	0.779	84	73	43	41	37
	NCI-H460	0.362	1.562	0.342	0.228	0.171	0.140	0.124	-6	-37	-53	-61	-66
	NCI-H522	0.374	0.760	0.722	0.705	0.691	0.674	0.657	90	86	82	78	73
	COLO 205	0.145	0.814	0.028	0.025	0.015	0.021	0.021	-80	-83	-90	-86	-86
	HCC-2998	0.334	0.742	0.538	0.354	0.291	0.360	0.235	50	5	-13	-22	-30
	HCT-116	0.385	1.855	0.726	0.483	0.389	0.348	0.349	23	7	0	-10	-9
	HCT-15	0.205	1.183	0.279	0.211	0.144	0.128	0.125	8	1	-30	-38	-39
CNS Cancer	H29	0.322	1.477	1.515	1.485	1.404	1.462	1.446	103	101	94	99	97
	KM12	0.240	1.440	1.235	1.190	0.922	0.865	0.799	83	79	57	52	47
	SW-620	0.134	0.962	0.849	0.744	0.674	0.632	0.607	86	74	65	60	57
	SV-268	0.360	0.874	0.891	0.873	0.886	0.901	0.898	103	100	102	105	105
	SV-295	0.512	1.273	0.862	0.728	0.636	0.670	0.603	46	28	16	21	12
	SV-519	0.220	1.040	1.006	0.820	0.632	0.528	0.574	96	73	50	38	43
	SNB-19	0.316	1.144	1.164	1.172	1.151	1.194	1.191	102	103	101	106	106
	SNB-75	0.326	0.663	0.623	0.637	0.618	0.634	0.589	88	92	87	91	78
	U751	0.197	0.980	0.913	0.909	0.814	0.833	0.876	91	91	79	81	87
	Melanoma												
Ovarian Cancer	LOX IMVI	0.349	1.657	1.606	1.494	1.415	1.380	1.464	96	88	81	79	85
	LMME-3M	0.350	0.690	0.710	0.663	0.671	0.647	0.647	106	103	92	94	87
	ML4	0.320	1.267	1.213	1.130	1.167	1.124	1.104	94	85	89	85	83
	SK-MEL-2	0.592	1.003	0.879	0.929	0.920	0.954	0.930	70	82	80	76	88
	SK-MEL-28	0.345	1.061	1.051	1.038	0.986	0.901	0.930	99	95	89	90	82
	SK-MEL-5	0.346	2.127	2.076	2.082	2.081	2.217	2.042	97	98	97	105	95
	UACC-257	0.612	1.245	1.289	1.256	1.199	1.189	1.113	107	102	93	91	79
	UACC-62	0.597	2.056	1.844	1.677	1.650	1.675	1.582	85	74	72	74	68
	IGROVI	0.209	0.916	0.947	0.982	0.912	0.960	0.973	104	109	99	106	108
	OVCA-3	0.434	1.456	0.983	0.787	0.765	0.658	0.651	54	34	32	22	21
Renal Cancer	OVCA-4	0.359	1.518	1.472	1.477	1.274	1.310	1.180	96	96	79	82	71
	OVCA-5	1.107	1.815	1.700	1.618	1.446	1.432	1.493	84	72	48	49	54
	OVCA-8	0.238	0.927	0.928	0.938	0.896	0.930	0.950	100	102	95	100	103
	SK-OV-3	0.450	1.167	1.126	1.123	1.077	1.162	1.175	94	94	87	99	101
	786-0	0.453	1.424	1.386	1.400	1.434	1.446	1.489	96	98	101	102	107
	A498	0.757	1.493	1.293	0.950	0.768	0.606	0.616	73	26	1	-20	-19
	ACHN	0.360	1.548	1.526	1.590	1.327	1.363	1.318	98	104	81	84	81
	CAXI-1	0.292	1.503	1.439	1.477	1.266	1.371	1.210	95	98	80	89	77
	RFX 393	0.546	1.208	1.172	1.170	1.087	1.086	1.058	95	94	82	82	76
	SN12C	0.511	1.155	1.055	1.072	1.050	1.080	1.064	85	87	84	88	86
Prostate Cancer	TK-10	0.539	1.080	1.060	0.975	0.839	0.756	0.756	96	81	74	56	40
	UO-31	0.580	1.342	1.334	1.361	1.391	1.387	1.439	99	102	106	106	113
	PC-3	0.332	0.886	0.758	0.746	0.700	0.684	0.692	77	75	66	64	65
	DU-145	0.336	1.314	1.249	1.215	1.052	0.842	0.766	93	90	73	52	44
	MDA-MB-231/ATCC	0.361	2.217	1.918	1.618	1.333	1.279	1.180	84	68	52	49	44
	MDA-MB-435	0.261	1.392	1.295	1.274	1.027	1.055	0.954	106	111	104	106	105
	BT-549	0.570	1.415	1.383	1.377	1.294	1.297	1.256	100	100	93	84	109
	T-47D	0.382	1.044	1.014	1.025	1.000	1.054	0.955	105	101	99	100	106
	MDA-MB-435	0.217	0.929	0.859	0.897	0.806	0.806	0.807	91	90	68	70	61
	MDA-MB-435	0.261	1.392	1.295	1.274	1.027	1.055	0.954	91	90	68	70	61

Fig. 21 A

16E2 Octopus (anti-DR5) - 6 day

Panel/Cell Line	Time Zero	Ctrl	Mean Optical Densities					Log10 Concentration					Percent Growth					TGI	GI50	LC50
			0.5 1.0 1.5 2.0					2.0 1.5 1.0 0.5					0.5 1.0 1.5 2.0							
Leukemia	CCR6-CEM	0.004	0.731	0.832	0.730	0.789	0.720	0.103	114	100	108	98	14	6.11E+01	>1.00E+02	>1.00E+02	>1.00E+02			
	HL-60(TB)	0.068	2.840	2.914	2.950	2.924	2.813	2.039	103	104	103	99	71	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02			
	K-562	0.046	2.941	2.912	2.718	2.776	2.799	2.688	99	92	94	95	91	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02			
	MOLT-4	0.009	0.981	0.450	0.287	0.266	0.282	0.196	45	29	26	28	19	<1.00E+00	>1.00E+02	>1.00E+02	>1.00E+02			
	RPMI-8226	0.061	1.637	0.904	0.725	0.604	0.584	0.618	53	42	34	33	35	1.43E+00	>1.00E+02	>1.00E+02	>1.00E+02			
	SR	0.031	2.631	0.642	0.261	0.136	0.091	0.110	24	9	4	2	3	<1.00E+00	>1.00E+02	>1.00E+02	>1.00E+02			
Non-Small Cell Lung Cancer	A549/ATCC	0.021	2.721	2.734	2.443	2.524	2.458	2.314	100	90	93	90	85	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02			
	ERXV	0.057	1.201	0.939	0.896	0.773	0.683	0.581	77	73	63	55	46	5.80E+01	>1.00E+02	>1.00E+02	>1.00E+02			
	HOP-62	0.059	0.922	0.750	0.767	0.683	0.595	0.541	80	82	72	62	56	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02			
	HOP-92	0.110	0.792	0.642	0.573	0.577	0.525	0.512	78	68	69	61	59	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02			
	NCI-H23	0.103	1.191	1.103	1.027	1.069	1.034	1.057	92	85	89	86	88	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02			
	NCI-H322M	0.038	1.051	0.841	0.716	0.858	0.965	0.826	79	67	81	92	78	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02			
Colon Cancer	NCI-H460	0.050	2.780	1.042	0.668	0.339	0.459	0.387	36	23	13	15	12	<1.00E+00	>1.00E+02	>1.00E+02	>1.00E+02			
	NCI-H522	0.064	0.648	0.481	0.406	0.386	0.409	0.307	71	59	55	59	42	5.77E+01	>1.00E+02	>1.00E+02	>1.00E+02			
	COLO 205	0.001	1.430	-0.014	-0.033	-0.014	-0.014	-0.013	-100	-100	-100	-100	-100	<1.00E+00	<1.00E+00	<1.00E+00	<1.00E+00			
	HCC-2998	0.031	0.974	0.296	0.096	0.067	0.047	0.036	28	7	4	2	1	<1.00E+00	>1.00E+02	>1.00E+02	>1.00E+02			
	HCT-116	0.068	2.951	2.404	2.329	2.028	1.901	1.691	81	78	68	64	56	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02			
	HCT-15	0.020	2.056	0.435	0.168	0.100	0.096	0.107	20	7	4	4	4	<1.00E+00	>1.00E+02	>1.00E+02	>1.00E+02			
CNS Cancer	HT29	0.052	2.528	2.445	2.325	2.293	2.387	2.210	97	92	91	94	87	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02			
	KM12	0.010	0.708	0.390	0.334	0.486	0.290	0.283	54	46	68	40	39	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02			
	SW-620	0.010	2.141	1.392	1.302	1.282	1.145	0.966	65	61	60	53	45	4.95E+01	>1.00E+02	>1.00E+02	>1.00E+02			
	SF-268	0.041	1.069	1.017	0.969	0.993	0.980	0.958	95	90	93	91	89	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02			
	SF-295	0.054	1.614	0.031	0.019	0.018	0.023	0.023	-43	-66	-67	-57	-57	<1.00E+00	>1.00E+00	1.45E+00	>1.00E+02			
	SF-539	0.030	1.468	0.875	0.672	0.624	0.646	0.572	59	45	41	43	38	2.05E+00	>1.00E+02	>1.00E+02	>1.00E+02			
Melanoma	SK-MEL-2	0.083	0.498	0.209	0.160	0.166	0.151	0.153	30	19	20	16	17	<1.00E+00	>1.00E+02	>1.00E+02	>1.00E+02			
	SK-MEL-28	0.045	1.316	0.703	0.668	0.603	0.524	0.478	52	49	44	38	34	2.11E+00	>1.00E+02	>1.00E+02	>1.00E+02			
	SK-MEL-5	0.095	1.885	1.902	1.947	1.880	1.916	1.895	101	103	100	102	101	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02			
	UACC-257	0.070	0.841	0.504	0.447	0.420	0.393	0.376	56	49	45	42	40	2.64E+00	>1.00E+02	>1.00E+02	>1.00E+02			
	UACC-62	0.121	1.601	1.119	0.932	0.781	0.764	0.810	67	55	45	43	47	5.44E+00	>1.00E+02	>1.00E+02	>1.00E+02			
	IGROV1	0.018	1.567	1.476	1.603	1.622	1.529	1.510	94	102	104	98	96	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02			
Ovarian Cancer	OVCA2-3	0.086	1.285	0.039	0.041	0.039	0.040	0.033	-55	-52	-55	-53	-62	<1.00E+00	<1.00E+00	<1.00E+00	<1.00E+00			
	OVCA2-4	0.071	1.563	1.304	1.287	1.028	0.998	0.854	83	81	64	62	52	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02			
	OVCA2-5	0.101	1.606	1.390	1.053	1.046	0.873	0.837	86	63	63	51	49	5.85E+01	>1.00E+02	>1.00E+02	>1.00E+02			
	OVCA2-8	0.020	1.565	1.634	1.571	1.587	1.630	1.570	104	100	101	104	100	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02			
	SK-OV-3	0.056	0.811	0.817	0.812	0.813	0.759	0.769	101	100	100	93	94	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02			
	786-O	0.073	1.715	1.716	1.715	1.726	1.731	1.686	100	100	101	101	98	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02			
Renal Cancer	A498	0.087	1.058	0.996	0.877	0.737	0.692	0.716	94	81	67	62	65	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02			
	ACHN	0.041	1.970	1.331	0.307	0.016	0.020	0.020	67	14	-61	-51	-51	1.44E+00	3.92E+00	8.46E+00	>1.00E+02			
	CAXI-1	0.033	1.215	0.797	0.758	0.492	0.535	0.512	65	61	39	42	41	5.66E+00	>1.00E+02	>1.00E+02	>1.00E+02			
	RFX 393	0.101	0.973	0.496	0.086	0.043	0.029	0.028	45	-15	-58	-71	-72	<1.00E+00	2.37E+00	8.08E+00	>1.00E+02			
	SN12C	0.054	1.263	0.669	0.504	0.358	0.315	0.249	51	37	25	22	16	1.08E+00	>1.00E+02	>1.00E+02	>1.00E+02			
	TK-10	0.057	1.064	1.000	0.925	0.811	0.666	0.568	94	86	75	60	51	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02			
Prostate Cancer	UO-31	0.095	1.457	1.201	0.838	0.701	0.476	0.418	81	55	44	28	24	5.32E+00	>1.00E+02	>1.00E+02	>1.00E+02			
	PC-3	0.030	0.879	0.520	0.379	0.334	0.315	0.333	58	41	36	34	36	1.70E+00	>1.00E+02	>1.00E+02	>1.00E+02			
Breast Cancer	DU-145	0.057	1.962	1.887	1.790	1.717	1.662	1.654	96	91	87	84	84	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02			
	MCF7	0.060	2.908	2.856	2.870	2.865	2.833	2.843	98	99	98	97	98	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02			
Breast Cancer	MDA/ADR-RES	0.045	1.087	1.064	1.054	1.157	1.130	1.088	98	97	107	104	100	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02			
	MDA-MB-231/ATCC	0.042	0.819	0.674	0.577	0.538	0.488	0.578	81	69	64	57	69	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02			
	HS 578T	0.055	0.759	0.470	0.322	0.261	0.260	0.201	59	38	29	29	21	1.64E+00	>1.00E+02	>1.00E+02	>1.00E+02			
	MDA-MB-435	0.041	2.284	1.227	0.955	0.806	0.723	0.531	53	41	34	35	30	1.32E+00	>1.00E+02	>1.00E+02	>1.00E+02			
	MDA-N	0.010	0.861	0.490	0.457	0.355	0.322	0.313	56	53	40	37	36	4.04E+00	>1.00E+02	>1.00E+02	>1.00E+02			
	BT-549	0.100	1.316	0.995	0.521	0.364	0.313	0.251	74	55	22	18	12	2.01E+00	>1.00E+02	>1.00E+02	>1.00E+02			
T-47D	0.049	0.626	0.613	0.564	0.528	0.526	0.613	98	89	83	83	98	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02				


Fig. 21 B

Figure 21B shows the results of the APO2L - 6 day assay. The data is presented in a table format, showing the mean optical densities (OD) and percent growth for various cell lines and treatments. The table is organized into columns for Time, Panel/Cell Line, Zero, Ctrl, Mean Optical Densities (0.5, 1.0, 1.5, 2.0), Percent Growth (0.5, 1.0, 1.5, 2.0), GI50, TGI, and LC50.

APO2L - 6 day

Panel/Cell Line	Time Zero	Ctrl	Mean Optical Densities				Log10 Concentration				Percent Growth				GI50	TGI	LC50
			0.5	1.0	1.5	2.0	0.5	1.0	1.5	2.0	0.5	1.0	1.5	2.0			
Leukemia	CCRF-CEM	0.004	0.842	0.753	0.453	0.365	0.574	0.569	89	54	43	68	67	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02
	HL-60(TB)	0.068	2.822	0.712	0.317	0.202	0.116	0.080	23	9	5	2	0	<1.00E+00	>1.00E+02	>1.00E+02	>1.00E+02
	K-562	0.046	2.792	0.929	0.317	0.202	0.116	0.080	106	108	105	97	94	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02
	MOLT-4	0.009	1.040	0.929	0.928	0.965	0.999	0.797	89	89	93	96	76	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02
	RPMT-8226 SR	0.061 0.031	1.661 2.591	0.072 2.540	0.038 2.234	0.041 1.915	0.025 1.822	0.022 1.708	1 98	-39 86	-34 74	-59 70	-65 65	<1.00E+00 >1.00E+02	>1.00E+02 >1.00E+02	>1.00E+02 >1.00E+02	>1.00E+02 >1.00E+02
Non-Small Cell Lung Cancer	AS49/APCC	0.021	2.037	2.071	2.070	2.029	2.045	2.038	102	102	100	100	100	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02
	EAHY	0.057	1.052	1.070	1.039	1.078	1.000	0.962	102	99	103	95	91	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02
	HOP-62	0.039	0.891	0.854	0.854	0.787	0.725	0.662	96	95	87	80	72	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02
	HOP-92	0.110	0.906	0.750	0.698	0.700	0.705	0.723	80	74	74	75	77	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02
	MCI-H23	0.103	1.184	1.180	1.147	1.122	1.185	1.163	100	97	94	100	98	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02
Colon Cancer	MCI-H322H	0.038	0.976	0.824	0.606	0.488	0.436	0.346	84	60	48	42	33	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02
	MCI-H460	0.050	2.857	0.536	0.239	0.153	0.063	0.048	17	7	4	0	-4	<1.00E+00	>1.00E+02	>1.00E+02	>1.00E+02
	MCI-H522	0.064	0.461	0.354	0.344	0.336	0.263	0.238	73	70	68	50	44	<1.00E+00	>1.00E+02	>1.00E+02	>1.00E+02
	COLO 205	0.001	1.396	-0.005	-0.007	0.006	0.002	0.014	-100	-100	0	0	1	<1.00E+00	>1.00E+02	>1.00E+02	>1.00E+02
	HCC-2998	0.031	1.083	0.682	0.274	0.305	0.202	0.189	62	23	26	16	15	<1.00E+00	>1.00E+02	>1.00E+02	>1.00E+02
CNS Cancer	HCT-116	0.068	3.014	2.272	1.606	1.249	0.953	0.821	75	52	40	30	26	<1.00E+00	>1.00E+02	>1.00E+02	>1.00E+02
	HCT-15	0.020	2.169	0.196	0.054	0.039	0.018	0.030	8	2	1	-10	0	<1.00E+00	>1.00E+02	>1.00E+02	>1.00E+02
	HX29	0.052	1.968	1.970	1.962	2.035	2.034	2.063	100	100	103	103	105	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02
	KX12	0.010	0.633	0.249	0.218	0.133	0.052	0.052	38	33	20	7	7	<1.00E+00	>1.00E+02	>1.00E+02	>1.00E+02
	SW-620	0.010	2.236	1.477	1.220	1.040	0.943	0.608	66	54	46	42	27	<1.00E+00	>1.00E+02	>1.00E+02	>1.00E+02
Melanoma	LOX IMVI	0.037	3.184	2.701	2.366	2.418	2.050	2.276	85	74	76	64	71	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02
	M14	0.035	1.827	1.721	1.740	1.634	1.636	1.551	62	41	36	31	30	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02
	SF-235	0.054	1.659	1.054	0.706	0.634	0.557	0.529	93	68	73	68	44	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02
	SF-539	0.030	1.513	1.411	1.046	1.113	1.034	0.689	93	68	73	68	44	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02
	SK-MEL-5	0.045	1.350	1.130	1.163	1.105	1.015	0.843	83	86	81	74	61	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02
Ovarian Cancer	SK-MEL-28	0.095	1.718	1.748	1.792	1.711	1.824	2.003	102	105	100	107	118	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02
	UACC-257	0.070	0.830	0.756	0.716	0.744	0.692	0.664	90	85	89	82	78	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02
	UACC-62	0.121	1.729	1.649	1.630	1.410	1.396	1.459	95	94	80	79	83	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02
	IGROV1	0.018	1.901	1.898	1.794	1.820	1.801	1.734	100	94	96	95	91	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02
	OVCAR-3	0.086	1.293	0.097	0.073	0.049	0.032	0.037	1	-16	-43	-63	-57	<1.00E+00	>1.00E+02	>1.00E+02	>1.00E+02
Renal Cancer	OVCAR-4	0.071	1.553	1.364	1.289	1.245	1.060	1.102	87	82	79	67	70	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02
	OVCAR-5	0.101	1.436	1.357	1.289	1.246	1.206	1.149	94	87	86	83	78	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02
	OVCAR-8	0.020	1.641	1.540	1.606	1.595	1.634	1.608	94	98	97	100	98	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02
	SK-OV-3	0.056	0.848	0.834	0.807	0.853	0.821	0.834	98	95	101	97	98	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02
	786-0	0.073	1.816	1.818	1.830	1.853	1.816	1.834	100	101	102	100	101	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02
Prostate Cancer	A498	0.087	1.108	1.080	1.046	1.034	0.988	0.969	97	94	93	88	86	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02
	ACHN	0.041	2.105	2.060	2.051	1.993	1.958	1.867	98	97	95	93	88	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02
	CAXI-1	0.033	1.080	1.108	0.941	1.017	1.031	0.959	103	87	94	95	88	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02
	RFX 393	0.101	0.982	0.589	0.322	0.362	0.450	0.262	55	25	30	40	18	<1.00E+00	>1.00E+02	>1.00E+02	>1.00E+02
	SN12C	0.054	1.352	1.354	1.353	1.319	1.346	1.257	100	100	97	100	93	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02
Breast Cancer	TK-10	0.057	1.226	1.159	1.058	1.042	0.939	0.802	94	86	84	75	64	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02
	UO-31	0.095	1.523	1.434	1.395	1.377	1.343	1.340	94	91	90	87	87	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02
	PC-3	0.030	0.817	0.520	0.467	0.384	0.426	0.342	62	56	45	50	40	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02
	DJ-145	0.057	1.911	1.810	1.744	1.693	1.539	1.024	95	91	88	70	52	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02
	MCF7	0.060	3.104	2.284	2.012	1.444	0.809	0.770	73	64	45	25	23	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02
Breast Cancer	MCF/ADR-RES	0.045	1.013	1.037	1.036	1.017	1.007	0.974	102	102	100	99	96	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02
	MDA-MB-231/ATCC	0.042	0.873	0.774	0.755	0.805	0.750	0.720	88	86	92	85	82	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02
	HS 578T	0.055	0.491	0.512	0.511	0.508	0.518	0.515	105	105	104	106	106	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02
	MDA-MB-435	0.041	2.083	2.007	1.758	1.719	1.519	1.387	96	84	82	72	66	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02
	MDA-N	0.010	0.984	0.809	0.738	0.803	0.677	0.571	82	75	81	68	58	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02
Breast Cancer	BT-549	0.100	1.236	1.457	1.398	1.377	1.346	1.346	113	109	107	111	104	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02
	T-47D	0.049	0.567	0.582	0.568	0.595	0.566	0.490	103	100	105	100	85	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02

Fig. 22



Size comparison of Octopus Constructs:









Figure 24 shows the construction of the Octopus heavy chain in pRK vector. The diagram illustrates the cloning strategy, including the PCR amplification of the Leu zipper vector (VG15) and the subsequent cloning of the Octopus heavy chain into the pRK vector.




Fig. 24




Fig. 25





Fig. 26



Representative plot of $n = 6$ cytostasis assays; crystal violet

Fig. 27




Fig. 28A




Fig. 28B

OctHER2..... POPoct-3HER2——

○● Unbound □■ Cell surface bound ▲△ Intracellular ◇◇ Catabolized




Fig. 29A

Fig. 29B




Fig. 30A




Fig. 30B

$n = 4$ apoptosis assays
Crystal violet

Fig. 31A




Fig. 31B




Fig. 32




Fig. 33





Fig. 34



OctCD20

● Unbound ■ Catabolized ◆ Cell surface bound ▲ Intracellular




Fig. 35